Mobile

A Clinical Trial to observe the effects of the test drug Rovalpituzumab Tesirine in patients with a particular form of Lung Cancer where no lasting efficacy has been achieved on at least two previous ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-004506-42

A Clinical Trial to observe the effects of the test drug Rovalpituzumab Tesirine in patients with a particular form of Lung Cancer where no lasting efficacy has been achieved on at least two previous therapies

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To investigate the efficacy of rovalpituzumab tesirine as third-line and later treatment for subjects with relapsed or refractory delta-like protein 3 (DLL3)-expressing small cell lung cancer (SCLC)

Critère d'inclusion

  • Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer

Liens